Sociedad Americana de Hirudoterapia

Free flap take-back following postoperative microvascular compromise: predicting salvage versus failure

Research article published in Plastic and reconstructive surgery (2012)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosMirzabeigi et al. · Plastic and reconstructive surgery, 2012

Abstract

BACKGROUND: The purpose of this study is twofold: (1) to stratify preoperative risk factors that predict successful free flap salvage and (2) to identify perioperative strategies that correlate with successful salvage. METHODS: A retrospective chart review was performed on all free flaps performed from January of 2005 to April of 2011. The time until salvage was defined as the end of the initial procedure until the initiation of the salvage attempt. The primary endpoint, successful salvage, was defined as any flap that did not result in total loss. RESULTS: A total of 2260 free flaps were reviewed, and 47 take-backs for delayed microvascular compromise were identified. Twenty-three of 47 flaps (49 percent) were salvaged. The mean time until take-back, presence of thrombophilia, and preoperative platelet counts were factors predictive of unsuccessful salvage. Preoperative platelet counts above 300 were associated with the lowest rates of salvage. Intraoperative maneuvers were examined, and surgeon experience (defined as >5 years in practice) was the only factor that was significant; however, intraoperative heparin anticoagulation and complete mechanical thrombectomy trended toward significance. The type of thrombolytic agent used was not found to result in a statistically significant difference. CONCLUSIONS: There is evidence to suggest that there may be preoperative factors predictive of flap salvage success, including thrombophilia and routine preoperative platelet values. Shorter time to take-back and surgeon experience may improve salvage, whereas intraoperative heparin anticoagulation and complete mechanical removal of the thrombus demonstrate preliminary evidence as effective intraoperative strategies.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsFree Tissue FlapsHumansMicrovesselsMiddle AgedMonitoring, IntraoperativePlatelet CountPostoperative ComplicationsPreoperative CareReoperationRetrospective StudiesRisk FactorsSalvage Therapy

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Esta revisión retrospectiva de 2.260 colgajos libres identificó 47 reingresos por compromiso microvascular retrasado, de los cuales 23 (49 por ciento) fueron salvados, y encontró que el mayor tiempo hasta el reingreso, la trombofilia y los recuentos plaquetarios preoperatorios más altos predijeron el fracaso, mientras que el menor tiempo hasta la reexploración y la mayor experiencia quirúrgica favorecieron la salvación; la heparina intraoperatoria y la trombectomía completa mostraron solo una asociación de nivel de tendencia. Para la ASH, esto se corresponde con el territorio clínico donde se utilizan sanguijuelas: el compromiso venoso de colgajos libres, donde la descongestión gana tiempo para la microvasculatura. El resumen no menciona la terapia con sanguijuelas y se centra en la anticoagulación quirúrgica y farmacológica en lugar de la hirudoterapia, por lo que plantea el problema de la salvación que las sanguijuelas abordan sin hablar de las sanguijuelas en sí mismas. Como un estudio retrospectivo de una sola institución, sus predictores son asociaciones, no causas probadas, y la tasa de salvación refleja la mezcla de casos de este centro.

Citación

Free flap take-back following postoperative microvascular compromise: predicting salvage versus failure.

Mirzabeigi et al. · Plastic and reconstructive surgery, 2012

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.